Abionyx Pharma
ABNX
Company Profile
Business description
Abionyx Pharma is a new generation biotech company dedicated to the discovery and development of innovative therapies for patients without existing or effective treatment. The biotech assets inherited from CERENIS Therapeutics constitute a portfolio of valuable programs for the treatment of cardiovascular diseases and associated metabolic diseases such as NAFLD and NASH as well as an HDL targeted drug delivery platform in oncology, more specifically in Immuno oncology and chemotherapy.
Contact
33-43 Avenue Georges Pompidou-Bat D2
Balma31130
FRAT: +33 562249706
Sector
Healthcare
Stock type
Defensive
Industry
Biotechnology
Fiscal Year End
31 December 2025
Employees
51
Stocks News & Analysis
stocks
AI stocks post big gains in Q3. These are the winners and losers
Alphabet and Teradyne post big gains, while Salesforce and Adobe were down in the quarter.
stocks
12 picks for an income portfolio - Q3 2025 update
Fifteen months in and passive income growth has exceeded my target.
stocks
ASX’s only dividend aristocrat reports
Cyclical headwinds persist but loan book and industrial property prop up earnings.
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 9,280.00 | 38.90 | -0.42% |
| CAC 40 | 7,971.78 | 109.76 | -1.36% |
| DAX 40 | 24,378.29 | 0.51 | -0.00% |
| Dow JONES (US) | 46,694.97 | 63.31 | -0.14% |
| FTSE 100 | 9,479.14 | 12.11 | -0.13% |
| HKSE | 26,957.77 | 183.15 | -0.67% |
| NASDAQ | 22,941.67 | 161.16 | 0.71% |
| Nikkei 225 | 47,944.76 | 2,175.26 | 4.75% |
| NZX 50 Index | 13,478.57 | 10.67 | -0.08% |
| S&P 500 | 6,740.28 | 24.49 | 0.36% |
| S&P/ASX 200 | 8,981.40 | 34.80 | -0.39% |
| SSE Composite Index | 3,882.78 | 20.25 | 0.52% |